Engineering Nano‐ and Microparticles as Oral Delivery Vehicles to Promote Intestinal Lymphatic Drug Transport

• Published in: Advanced materials (Weinheim) Vol. 33; no. 51; pp. e2104139 - n/a
• Main Authors: Miao, Yang‐Bao, Lin, Yu‐Jung, Chen, Kuan‐Hung, Luo, Po‐Kai, Chuang, Shun‐Hao, Yu, Yu‐Tzu, Tai, Hsien‐Meng, Chen, Chiung‐Tong, Lin, Kun‐Ju, Sung, Hsing‐Wen
• Format: Journal Article
• Language: English
• Published: Germany Wiley Subscription Services, Inc 01.12.2021
• Subjects: Chemical compounds; enterocyte; intestinal lymphatic system; M cell; Materials science; Microparticles; mRNA Vaccines; Nucleic acids; oral drug delivery; Pharmacology; Vaccines; Vehicles; β‐glucans; intestinal lymphatic system; M cell; β-glucans; enterocyte; oral drug delivery
• ISSN: 0935-9648; 1521-4095; 1521-4095
• DOI: 10.1002/adma.202104139

Targeted oral delivery of a drug via the intestinal lymphatic system (ILS) has the advantages of protecting against hepatic first‐pass metabolism of the drug and improving its pharmacokinetic performance. It is also a promising route for the oral delivery of vaccines and therapeutic agents to induce mucosal immune responses and treat lymphatic diseases, respectively. This article describes the anatomical structures and physiological characteristics of the ILS, with an emphasis on enterocytes and microfold (M) cells, which are the main gateways for the transport of particulate delivery vehicles across the intestinal epithelium into the lymphatics. A comprehensive overview of recent advances in the rational engineering of particulate vehicles, along with the challenges and opportunities that they present for improving ILS drug delivery, is provided, and the mechanisms by which such vehicles target and transport through enterocytes or M cells are discussed. The use of naturally sourced materials, such as yeast microcapsules and their derived polymeric β‐glucans, as novel ILS‐targeting delivery vehicles is also reviewed. Such use is the focus of an emerging field of research. Their potential use in the oral delivery of nucleic acids, such as mRNA vaccines, is proposed. The rational engineering of effective vehicles for lymphatic delivery of drugs, through targeting enterocytes or M cells, prevents their first‐pass metabolism by the liver, markedly increasing the bioavailability of oral drugs. By achieving increased bioavailability, high drug concentrations are attainable at the lesions of interest with beneficial therapeutic effects, making intestinal lymphatic transport a unique modality of drug delivery.